APremilast After FumaRic Acid Ester Treatment
- Sponsor
- Amgen
- Study ID
- NCT02954081
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Phase I: Fumaric acid esters. Phase II: Apremilast — DRUGApremilast
Study Details
Patient treatment preference and treatment satisfaction of physicians and patients comparing fumaric acid ester therapy with subsequent apremilast treatment
Key Dates
- First listed
- Nov 3, 2016
- Start date
- Jan 26, 2017
- Status verified
- Jan 2023
- Primary completion
- Aug 15, 2022
- Completion
- Aug 15, 2022
Study Design
- Enrollment
- 687 participants (actual)
Primary Outcome Measure
Mean absolute value of the overall TSQM score at week 24 of apremilast (APR) therapy (phase II). [ Time Frame: 56 weeks ]
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey